-$0.09 Earnings Per Share Expected for Phio Pharmaceuticals Corp (NASDAQ:PHIO) This Quarter
Equities analysts expect that Phio Pharmaceuticals Corp (NASDAQ:PHIO) will announce earnings of ($0.09) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Phio Pharmaceuticals’ earnings. Phio Pharmaceuticals posted earnings of ($0.10) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 10%. The firm is scheduled to announce its next earnings results on Wednesday, March 25th.
On average, analysts expect that Phio Pharmaceuticals will report full-year earnings of ($0.36) per share for the current financial year. For the next fiscal year, analysts forecast that the business will report earnings of ($0.35) per share. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Phio Pharmaceuticals.
Phio Pharmaceuticals (NASDAQ:PHIO) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08).
PHIO stock traded down $0.03 during trading on Monday, hitting $0.24. 421,200 shares of the stock traded hands, compared to its average volume of 350,896. Phio Pharmaceuticals has a one year low of $0.19 and a one year high of $0.52. The stock has a market cap of $8.19 million, a price-to-earnings ratio of -0.23 and a beta of 1.63. The company has a 50 day simple moving average of $0.24 and a 200 day simple moving average of $0.35. The company has a current ratio of 5.87, a quick ratio of 5.87 and a debt-to-equity ratio of 0.05.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
Featured Article: What is Compound Interest?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.